Immunotherapy最新文献_第8页

Plain language summary: Headache and migraine experiences in people with primary immunodeficiency receiving GAMMAPLEX® 5% or 10% intravenous immunoglobulin therapy. 简明语言总结：接受GAMMAPLEX®5%或10%静脉注射免疫球蛋白治疗的原发性免疫缺陷患者的头痛和偏头痛经历。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-02-01 Epub Date: 2026-03-03 DOI: 10.1080/1750743X.2026.2633976

Bob Geng, Kim Clark

引用次数: 0

Advances in immunotherapy for cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation. 异基因造血干细胞移植后巨细胞病毒感染的免疫治疗进展。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-02-01 Epub Date: 2026-03-18 DOI: 10.1080/1750743X.2026.2644106

Yu Wang, Jiaying Wu, Xiaobing Huang, Yi Xiao

{"title":"Advances in immunotherapy for cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation.","authors":"Yu Wang, Jiaying Wu, Xiaobing Huang, Yi Xiao","doi":"10.1080/1750743X.2026.2644106","DOIUrl":"10.1080/1750743X.2026.2644106","url":null,"abstract":"Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective curative therapy for hematologic malignancies. However, post-transplant cytomegalovirus (CMV) infection remains a common and serious complication, significantly impacting patient prognosis and survival. Currently available antiviral agents are limited by bone marrow suppression, nephrotoxicity, drug resistance, and high cost, highlighting the need for alternative therapeutic strategies. Advances in immunotherapy - including CMV-specific T cells (CMV-CTL), TCR-engineered T cells (CMV-TCR-T), and natural killer (NK) cell therapies - as well as antibody-based approaches and prophylactic vaccines, provide new avenues for CMV management. Future treatment paradigms may integrate antiviral therapy, immunotherapy, and vaccination to improve outcomes in patients experiencing CMV reactivation after transplantation. This review summarizes the current progress of immunotherapeutic strategies for CMV infection following allo-HSCT. Relevant literature was identified through PubMed, Embase, and Web of Science databases, covering the period from January 2000 to December 2025.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"117-129"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13094259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147480578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of bronchoscopic cryoimmunotherapy in non-small cell lung cancer: current evidence and future perspectives. 支气管镜冷冻免疫治疗在非小细胞肺癌中的作用：目前的证据和未来的展望。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-02-01 Epub Date: 2026-04-16 DOI: 10.1080/1750743X.2026.2651072

Phillip N Perez, Illaa Smesseim, Daniel H Sterman

{"title":"The role of bronchoscopic cryoimmunotherapy in non-small cell lung cancer: current evidence and future perspectives.","authors":"Phillip N Perez, Illaa Smesseim, Daniel H Sterman","doi":"10.1080/1750743X.2026.2651072","DOIUrl":"10.1080/1750743X.2026.2651072","url":null,"abstract":"Lung cancer is the leading cause of cancer deaths, and despite therapeutic advances, recurrence and resistance persist. Local tumor ablation can function as an in situ vaccine, but thermal techniques may disrupt antigen and extracellular matrix integrity, potentially limiting immunogenicity, whereas cryoablation has been shown to preserve tumor antigens and matrix architecture while inducing immunogenic cell death. Bronchoscopic cryoimmunotherapy (BCI) aims to prime antitumor immunity rather than achieve complete tumor eradication. We review preclinical and clinical studies evaluating cryoablation and BCI in non-small cell lung cancer (NSCLC), focusing on immune mechanisms, delivery approaches, and combination with systemic therapies, particularly immune checkpoint inhibitors (ICIs). Preclinical models demonstrate that cryoablation releases danger signals and intact tumor antigens, drives dendritic cell maturation, expands effector CD8+ T cells, and activates STING-dependent type I interferon pathways. Early-phase human studies of BCI monotherapy show systemic immune stimulation, including reductions in the derived neutrophil-to-lymphocyte ratio and expansion of CD8+ effector memory populations. Combination cryoablation-ICI regimens have revealed improved response rates in some cohorts, although clinical outcomes have been limited by small, heterogeneous, and non-randomized studies. BCI is a mechanistically compelling, minimally invasive therapy, but its clinical benefit remains unproven and warrants rigorous randomized evaluation.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"237-247"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13155028/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147689969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Financial barriers to immunotherapy: challenges and potential mitigation strategies: a review paper. 免疫疗法的财政障碍：挑战和潜在的缓解战略：综述文件。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-02-01 Epub Date: 2026-03-02 DOI: 10.1080/1750743X.2026.2639275

Hasan Numan, Arafat Tfayli

{"title":"Financial barriers to immunotherapy: challenges and potential mitigation strategies: a review paper.","authors":"Hasan Numan, Arafat Tfayli","doi":"10.1080/1750743X.2026.2639275","DOIUrl":"10.1080/1750743X.2026.2639275","url":null,"abstract":"Introduction: Since the ipilimumab's approval in 2011, immune checkpoint inhibitors (ICIs) have become an integral aspect of oncology practice, offering unparalleled survival benefits across various cancers. Financial toxicities associated with the high pricing of ICIs have put a major constraint on their incorporation into oncology practice. Financial barriers of ICIs are particularly more pronounced in low-middle-income countries (LMICs).Areas covered: This review aimed to summarize financial barriers associated with the integration of immunotherapy into oncology practice, including dosing, pharmacoeconomic insufficiencies, flat-dosing overuse, out-of-pocket expenditures in LMICs, and structural barriers to access, such as limited reimbursement, and lack of biosimilars. We integrated evidence on dose optimization, de-escalation strategies, and health-care policies that can mitigate costs. Furthermore, we outlined the under-representation of LMICs in trials and the limited evidence on low-dose strategies from prospective data.Literature search: We performed a comprehensive literature review on PubMed and Google Scholar for English-language studies published between 2014 and 2025 using terms related to \"immunotherapy,\" \"financial toxicity,\" \"dose optimization,\" and 'low- and middle-income countries.\"Commentary: Dose-optimization strategies can reduce costs without compromising clinical efficacy, especially where financial barriers threaten continuity of care. Priorities include, prospective trials validating reduced dosing and international partnerships to integrate LMICs into research.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"89-97"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13094208/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147344089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MicroRNA prognostic markers for immune checkpoint inhibitor success in urologic cancers. 免疫检查点抑制剂在泌尿系统癌症中成功的MicroRNA预后标志物。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-02-01 Epub Date: 2026-03-10 DOI: 10.1080/1750743X.2026.2640756

Panagiotis J Vlachostergios, Konstatinos Evmorfopoulos, Konstantinos Marsitopoulos, Ioannis Tamposis, Maria Samara, Eleni Thodou, Panagiotis Sarantis, Dimitrios Matthaios, Michalis V Karamouzis, Vassilios Tzortzis, Antonis Giakountis

{"title":"MicroRNA prognostic markers for immune checkpoint inhibitor success in urologic cancers.","authors":"Panagiotis J Vlachostergios, Konstatinos Evmorfopoulos, Konstantinos Marsitopoulos, Ioannis Tamposis, Maria Samara, Eleni Thodou, Panagiotis Sarantis, Dimitrios Matthaios, Michalis V Karamouzis, Vassilios Tzortzis, Antonis Giakountis","doi":"10.1080/1750743X.2026.2640756","DOIUrl":"10.1080/1750743X.2026.2640756","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) have significantly transformed the treatment landscape of urologic malignancies, including bladder cancer, renal cell carcinoma (RCC), and prostate cancer. Despite impressive clinical responses in subsets of patients, the heterogeneity of response highlights the urgent need for robust prognostic biomarkers. MicroRNAs (miRNAs) - small non-coding RNAs that regulate gene expression post-transcriptionally - have emerged as pivotal players in tumor immune regulation and cancer progression. This review synthesizes current evidence on miRNA prognostic markers predictive of ICI success in urologic cancers, emphasizing their biological functions, clinical utility, and therapeutic implications. We discuss miRNA signatures with prognostic value, their mechanisms modulating immune checkpoints, and prospects for integrating miRNA profiling into personalized immunotherapy strategies. This work provides the first cancer-type - stratified synthesis linking mechanistic data, circulating biomarkers, and therapeutic modulation on miRNAs and ICIs in urologic cancers.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"99-116"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13094240/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147390045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of tarlatamab, a DLL3-targeted bispecific T-cell engager, in a patient with advanced esophageal small-cell neuroendocrine carcinoma: a case report. tarlatamab（一种dll3靶向双特异性t细胞结合剂）治疗晚期食管小细胞神经内分泌癌的疗效和安全性：1例报告

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-02-01 Epub Date: 2026-03-28 DOI: 10.1080/1750743X.2026.2652156

Bahadır Köylü, Cevat İlteriş Kıkılı, Fatih Kemik, Nazan Demir, Orhun Çığ Taşkın, Afak Durur Karakaya, Shaheenah Dawood, Fatih Selçukbiricik

{"title":"Efficacy and safety of tarlatamab, a DLL3-targeted bispecific T-cell engager, in a patient with advanced esophageal small-cell neuroendocrine carcinoma: a case report.","authors":"Bahadır Köylü, Cevat İlteriş Kıkılı, Fatih Kemik, Nazan Demir, Orhun Çığ Taşkın, Afak Durur Karakaya, Shaheenah Dawood, Fatih Selçukbiricik","doi":"10.1080/1750743X.2026.2652156","DOIUrl":"10.1080/1750743X.2026.2652156","url":null,"abstract":"The limited efficacy of current therapeutic options highlights a clear unmet need in patients with digestive neuroendocrine carcinoma. Tarlatamab is a bispecific T-cell engager targeting CD3 on T cells and delta-like ligand 3 on tumor cells. Since delta-like ligand 3 is highly expressed in digestive neuroendocrine carcinomas, tarlatamab might be a potential treatment option in this setting. However, the efficacy of tarlatamab in patients with digestive neuroendocrine carcinoma remains unknown. Herein, we report a case of metastatic esophageal neuroendocrine carcinoma that achieved a complete radiologic response following treatment with tarlatamab. A 47-year-old woman presented with progressive dysphagia and was diagnosed with esophageal small-cell neuroendocrine carcinoma with mediastinal lymph node metastases. She received first-line chemoimmunotherapy and radiotherapy to the primary tumor and mediastinal lymph nodes. Following three months of maintenance therapy with atezolizumab, new metastatic lesions in the liver and brain developed. Second-line treatment with tarlatamab was initiated. Tarlatamab induced complete resolution of the metastatic lesions in the liver and brain, without adverse events attributable to tarlatamab. This case underscores the potential value of delta-like ligand 3-targeted therapy with tarlatamab in metastatic digestive neuroendocrine carcinoma, a rare and highly aggressive malignancy with few effective treatment options.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"181-185"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13154954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147573678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oncolytic viruses in brain cancer therapy: advances, challenges, and clinical trial outcomes. 溶瘤病毒在脑癌治疗中的应用：进展、挑战和临床试验结果

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-02-01 Epub Date: 2026-05-04 DOI: 10.1080/1750743X.2026.2640755

Yaser Arjeini, Sara Khalili Dermani, Sanaz Sadeh, Elahe Abdolalipour, Masoumeh Saberpour, Hedieh Zargaran, Seyed Reza Mohebbi, Amir Ghaemi

{"title":"Oncolytic viruses in brain cancer therapy: advances, challenges, and clinical trial outcomes.","authors":"Yaser Arjeini, Sara Khalili Dermani, Sanaz Sadeh, Elahe Abdolalipour, Masoumeh Saberpour, Hedieh Zargaran, Seyed Reza Mohebbi, Amir Ghaemi","doi":"10.1080/1750743X.2026.2640755","DOIUrl":"10.1080/1750743X.2026.2640755","url":null,"abstract":"Malignant intracranial tumors are a major cause of morbidity and mortality across age groups. To assess recent progress in glioblastoma (GBM) oncolytic virotherapy, literature was searched in PubMed and Google Scholar using the keywords glioblastoma, oncolytic virus, clinical trials, brain tumor, and oncolytic virotherapy resistance. Relevant studies published through 2024 were reviewed. Brain tumors vary in prevalence, but many have poor prognosis and low survival rates. Among available treatment approaches, oncolytic virotherapy has gained strong attention as a promising cancer therapy. Existing evidence shows that oncolytic viruses (OVs) can produce meaningful anti-tumor effects; however, tumor cells may resist OV activity through several mechanisms. These include alterations in tumor-cell molecular pathways, features of the tumor microenvironment, and physiological barriers within the patient's body. Some OVs have completed in vitro and in vivo studies and are now being evaluated in clinical trials, while others remain in early preclinical development. Clinical success depends on the intrinsic anti-tumor activity of OVs, methods used to enhance them, and their ability to incorporate new genetic and antigenic features. Such modifications may improve immune evasion, tumor targeting, tumor lysis, and anti-tumor immune responses, supporting development of next-generation OVs.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"249-270"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13155027/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147814379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The game changer in the cervical cancer therapeutic landscape: immunotherapy. 宫颈癌治疗领域的游戏规则改变者：免疫疗法。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-02-01 Epub Date: 2026-04-10 DOI: 10.1080/1750743X.2026.2647581

Ramon Yarza, Lorena Fariñas-Madrid, Carmen García-Duran, David García-Illescas, Roberta Mazzeo, Irene Giannubilo, Ana Oaknin

{"title":"The game changer in the cervical cancer therapeutic landscape: immunotherapy.","authors":"Ramon Yarza, Lorena Fariñas-Madrid, Carmen García-Duran, David García-Illescas, Roberta Mazzeo, Irene Giannubilo, Ana Oaknin","doi":"10.1080/1750743X.2026.2647581","DOIUrl":"10.1080/1750743X.2026.2647581","url":null,"abstract":"Cervical cancer remains a major global health challenge, particularly in advanced stages where prognosis is poor despite recent therapeutic advances. The immunological landscape of cervical cancer offers a rationale for strategies aimed at enhancing tumor-specific immune responses. Based on this rational, several clinical trials have led to approval of immune checkpoint inhibitors for the treatment of Locally Advanced Cervical Cancer (CC) and Recurrent/Metastatic disease. The incorporation of Immune Checkpoint Inhibitors such as pembrolizumab and cemiplimab in the CC treatment has led to significant improvements in survival. However, primary and acquired resistance limits long-term efficacy, especially in patients with low PD-L1 expression or immunologically \"cold\" tumors. This review explores emerging immunotherapeutic approaches designed to overcome resistance, including novel checkpoint targets, tumor microenvironment modulation, therapeutic cancer vaccines, and adoptive cell therapies in cervical cancer. Early clinical data suggest that the combinations of these modalities may increase the proportion of patients who benefit from immunotherapy. Together, these strategies represent a dynamic immuno-oncology landscape with the potential to redefine treatment paradigms in cervical cancer. Ongoing clinical trials and translational studies will be key to identifying optimal combinations, timing, and patient populations most likely to derive durable benefit from these new interventions.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"205-221"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13154974/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147645085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness of first-line immune checkpoint inhibitor therapies, alone or combined with targeted agents, for unresectable hepatocellular carcinoma in China: an economic evaluation using network meta-analysis. 一线免疫检查点抑制剂治疗单独或联合靶向药物治疗不可切除肝细胞癌的成本效益：使用网络荟萃分析的经济评估

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-02-01 Epub Date: 2026-03-20 DOI: 10.1080/1750743X.2026.2647585

Wei Li, Li Wan, Sijie He

{"title":"Cost-effectiveness of first-line immune checkpoint inhibitor therapies, alone or combined with targeted agents, for unresectable hepatocellular carcinoma in China: an economic evaluation using network meta-analysis.","authors":"Wei Li, Li Wan, Sijie He","doi":"10.1080/1750743X.2026.2647585","DOIUrl":"10.1080/1750743X.2026.2647585","url":null,"abstract":"Objectives: This economic evaluation aimed to identify a cost-effective first-line treatment for unresectable hepatocellular carcinoma (uHCC) within China's healthcare system, specifically focusing on immune checkpoint inhibitor (ICI)-based regimens relevant to clinical practice, including newly approved options.Methods: Relative efficacy was synthesized from six phase III trials forming a star-shaped network with sorafenib as the common comparator, using a Bayesian network meta-analysis with Royston-Parmar models, accounting for non-proportional hazards. A 10-year, three-state partitioned survival model estimated discounted (5% annually) costs and quality-adjusted life-years (QALYs). Sensitivity analyses tested structural and parameter uncertainty.Results: After discounting, camrelizumab-rivoceranib provided more QALYs at a lower cost than three other ICI-based combinations (anlotinib-penpulimab, sintilimab-bevacizumab biosimilar, and toripalimab-bevacizumab), establishing strict dominance. The incremental cost per QALY gained was $10,715 for tislelizumab versus sorafenib, $56,796 for camrelizumab-rivoceranib versus tislelizumab, and $294,795 for atezolizumab-bevacizumab versus camrelizumab-rivoceranib. All findings remained robust in sensitivity analyses.Conclusions: For uHCC in China, tislelizumab represents a cost-effective choice at the current willingness-to-pay threshold of $40,344 per QALY (3×gross domestic product (GDP) per capita). This analysis provides timely evidence to inform clinical practice and policy decisions regarding the allocation of finite healthcare resources.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"169-179"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13154959/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147485674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Harnessing the gut microbiota in extra-intestinal cancers: from causal evidence to immunotherapy strategies. 利用肠道微生物群治疗肠外癌症：从因果证据到免疫治疗策略。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-02-01 Epub Date: 2026-03-24 DOI: 10.1080/1750743X.2026.2648431

Elisa Mattavelli, Valentina Da Prat, Salvatore Corallo, Alice Tartara, Simone Figini, Francesca De Simeis, Sofia Marino, Anna Uggè, Riccardo Caccialanza, Paolo Pedrazzoli, Angioletta Lasagna

{"title":"Harnessing the gut microbiota in extra-intestinal cancers: from causal evidence to immunotherapy strategies.","authors":"Elisa Mattavelli, Valentina Da Prat, Salvatore Corallo, Alice Tartara, Simone Figini, Francesca De Simeis, Sofia Marino, Anna Uggè, Riccardo Caccialanza, Paolo Pedrazzoli, Angioletta Lasagna","doi":"10.1080/1750743X.2026.2648431","DOIUrl":"10.1080/1750743X.2026.2648431","url":null,"abstract":"The gut microbiota (GM) has emerged as a key modulator of cancer development and therapeutic response beyond the gastrointestinal tract. In extra-intestinal cancers, GM composition influences oncogenesis, with specific microbial taxa and their metabolites linked to either increased or decreased cancer risk, as highlighted by Mendelian Randomization studies. Beyond cancer initiation, GM plays a critical role in shaping the efficacy and toxicity of anticancer therapies, particularly immunotherapy. We searched PubMed and ClinicalTrials.gov using the terms\"gut microbiota,\" \"immune checkpoint inhibitors,\" \"faecal microbiota transplantation,\" \"solid tumor\" in oncology patients. Evidence indicates that SCFA-producing bacteria, Akkermansia muciniphila, and members of Lachnospiraceae and Ruminococcaceae families enhance responses to immune checkpoint inhibitors (ICIs), whereas dysbiosis and immunosuppressive bacteria are associated with poor outcomes and immune-related adverse events. Therapeutic modulation of the GM through probiotics, prebiotics, fecal microbiota transplantation, and dietary interventions shows promise in optimizing immunotherapy efficacy, yet standardized clinical protocols remain lacking. Integrating GM profiling with multi-omics and artificial intelligence approaches offers a path toward personalized microbiota-targeted interventions to improve patient outcomes. This review critically summarizes current evidence linking GM to cancer immunotherapy, discusses mechanistic insights, and outlines future perspectives for translating microbiota modulation into clinical practice.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"223-235"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13154988/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147503875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0